Rocket Pharmaceuticals (NASDAQ: RCKT) seeks vote on director slate and option exchange
Rocket Pharmaceuticals (NASDAQ: RCKT) is holding its 2026 annual stockholder meeting on May 20, 2026, to vote on the election of seven directors, the ratification of EisnerAmper LLP as auditor, a non-binding advisory vote on executive pay, and the approval of a stock option exchange program. This virtual meeting will also address a 2025 strategic reorganization that reduced headcount by 30% and is expected to cut operating expenses by nearly 25%. The proposed stock option exchange program aims to enhance employee retention and motivation by allowing eligible employees to exchange "underwater" stock options for new options on a value-neutral basis, thereby reducing equity overhang.
Rocket gene therapy, among FDA’s March approvals, earns PRV
The FDA approved Rocket Pharmaceuticals' gene therapy Kresladi (marnetegragene autotemcel) on March 26 for leukocyte adhesion deficiency type I (LAD-1), making it the first BLA to pass CBER this year. The company expects to launch Kresladi by year-end and also received a rare pediatric disease priority review voucher. Last month's approvals also included four new molecular entities (NMEs).
[SC TO-C] ROCKET PHARMACEUTICALS, INC. Tender Offer Communication | RCKT SEC Filing - Form SC TO-C
This SEC filing (Form SC TO-C) by Rocket Pharmaceuticals, Inc. details a preliminary communication regarding a proposed stock option exchange program for its employees, excluding executive officers. The program would allow current employees to exchange certain stock options with a per-share exercise price equal to or higher than the company's trading price for new stock options on a value-neutral basis. The document emphasizes that this communication is not an offer and the program has not yet commenced, with a formal Tender Offer Statement on Schedule TO to be filed if the program proceeds.
RCKTW SEC Filings - ROCKET PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms
This article provides a comprehensive overview of ROCKET PHARMACEUTICALS (RCKTW) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It highlights recent Form 4 filings detailing acquisition/exercise transactions by Stevens Christopher James and equity awards for Sarbani Chaudhuri, as well as Rule 144 filings for share sales by various individuals. The platform also features AI-generated summaries, sentiment analysis, and historical stock performance data for each filing.
Rocket Pharmaceuticals, Inc. $RCKT Shares Acquired by JPMorgan Chase & Co.
JPMorgan Chase & Co. significantly increased its stake in Rocket Pharmaceuticals (NASDAQ:RCKT) by 73.6% in the third quarter, acquiring 889,231 additional shares, bringing their total holdings to over 2 million shares valued at approximately $6.84 million. Despite recent insider selling by executives, insiders still retain a substantial 24.76% ownership of the company. Analyst ratings are mixed, with a consensus "Hold" rating and an average price target of $13.86, while the stock currently trades around $3.58.
Rocket Pharmaceuticals Files $400M Mixed Shelf Offering, Opens Financing Doors
Rocket Pharmaceuticals (NASDAQ: RCKT) has announced a $400M mixed securities shelf offering and a $100M ATM program, signaling an attempt to secure future capital despite current stock declines. The company's financial position shows low debt but also a net loss from continuing operations. Despite a raised price target from Goldman Sachs, the bank issued a "Sell" rating, highlighting market hesitancy and the complex financial tightrope the company is walking.
FDA Approval Makes Rocket Pharma Gene Therapy the First for Ultra-Rare Immune Disorder
Rocket Pharmaceuticals received FDA approval for Kresladi, a gene therapy for the ultra-rare inherited immunodeficiency leukocyte-adhesion deficiency type 1 (LAD-I). This marks Rocket's first commercial product and is the first gene therapy approved for LAD-I, a condition often fatal in infancy. Although the market for LAD-I is small, the approval, which includes a rare pediatric disease priority review voucher, provides a positive outlook for Rocket's pipeline.
Rocket Pharma rises as FDA approves gene therapy
The article states that Rocket Pharma's stock is rising due to the FDA's approval of its gene therapy. No further details are provided as the content is incomplete.
Rocket Pharmaceuticals (RCKT) Stock Surges After FDA Approves Groundbreaking Gene Therapy
Rocket Pharmaceuticals (RCKT) shares jumped 9% following the FDA's accelerated approval of KRESLADI, a pioneering gene therapy for severe leukocyte adhesion deficiency-I (LAD-I) in pediatric patients. This approval marks the first FDA-cleared gene therapy for this rare and deadly immune disorder. The company also received a Rare Pediatric Disease Priority Review Voucher, which it plans to monetize.
Why Is Rocket Pharma Stock Soaring Friday?
Rocket Pharmaceuticals (NASDAQ: RCKT) stock is soaring Friday after the FDA granted accelerated approval to Kresladi (marnetegragene autotemcel), its gene therapy for severe leukocyte adhesion deficiency-I (LAD-I). This approval, based on strong clinical data demonstrating 100% overall survival and safety, marks the first FDA-approved gene therapy for this ultra-rare pediatric condition. The company also plans to monetize a Rare Pediatric Disease Priority Review Voucher to enhance financial flexibility.
Rocket Pharmaceuticals, Argan jump premarket; Two Harbors inches down
U.S. stock futures indicated a lower opening on Friday, while oil prices rose above $110 a barrel despite President Donald Trump's extension of a deadline for Iranian energy infrastructure attacks. Several companies experienced significant premarket動き: Rocket Pharmaceuticals and Lantern Pharma surged due to FDA approvals for their respective therapies, and Argan jumped on strong quarterly revenue. Conversely, Two Harbors Investment declined following its acquisition agreement.
US Premarket Movers: Argan, Rocket Pharmaceuticals, Unity
US stock futures, specifically the S&P 500 Index, fell by 0.3% due to China initiating investigations into US trade practices and Israel announcing an escalation of attacks on Iran. This report highlights key movers in the US premarket, including Argan, Rocket Pharmaceuticals, and Unity, signaling potential impacts on their stock performance. The article was published on March 27, 2026, at 11:54 AM UTC.
FDA clears Rocket Pharmaceuticals (RCKT) KRESLADI gene therapy and voucher
Rocket Pharmaceuticals announced that the FDA has granted accelerated approval for KRESLADI, an autologous hematopoietic stem cell gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) lacking a matched sibling donor. This approval also comes with a Rare Pediatric Disease Priority Review Voucher, which Rocket Pharmaceuticals plans to monetize for financial flexibility. The therapy is the first FDA-approved gene therapy for this life-threatening ultra-rare immunodeficiency.
Rocket Pharma Wins FDA Approval For KRESLADI — The First Ever Gene Therapy For Severe LAD-I
Rocket Pharmaceuticals Inc. has received accelerated FDA approval for KRESLADI, a gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I). This is the first gene therapy ever approved for LAD-I, a rare and life-threatening immunodeficiency. The approval follows a previous complete response letter and is based on clinical data showing restored CD18 and CD11a expression and clinical benefits in pediatric patients.
Rocket Pharmaceuticals Shares Fall 13% Despite FDA Approval For KRESLADI Gene Therapy
Rocket Pharmaceuticals' shares fell 13.22% on Friday, despite the company announcing FDA accelerated approval for KRESLADI, a gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I. The stock closed at $4.07, down from $4.69, with trading volume significantly above average. The approval also granted the company a Rare Pediatric Disease Priority Review Voucher, which they may monetize.
RCKT Stock Jumps Over 10% Premarket: FDA Approves Its First Gene Therapy For Rare Childhood Immune Disease
Rocket Pharmaceuticals (RCKT) shares surged over 10% premarket after the FDA approved its first gene therapy, Kresladi, for severe Leukocyte Adhesion Deficiency Type I (LAD-I). This approval marks a significant commercial milestone for the company and also granted them a Rare Pediatric Disease Priority Review Voucher. Kresladi is a single-infusion treatment using the patient's own modified stem cells, addressing a critical unmet need for children without matched sibling donors.
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals received accelerated FDA approval for KRESLADI™ (marnetegragene autotemcel), a gene therapy for pediatric patients with severe Leukocyte Adhesion Deficiency-I (LAD-I). This marks the first FDA-approved gene therapy for this rare and life-threatening immunodeficiency, for which the company also received a Rare Pediatric Disease Priority Review Voucher. KRESLADI aims to treat the underlying cause of severe LAD-I, a condition characterized by recurrent infections and poor prognosis without treatment.
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 9.3% - Should You Buy?
Rocket Pharmaceuticals (NASDAQ: RCKT) saw its shares jump 9.3% to approximately $4.67 on Wednesday, with trading volume slightly below its daily average. The company faces mixed analyst ratings, with an average "Hold" and a price target of $13.79, but recent targets range from a $3 "sell" to a $10 "overweight." Insider selling activity involved the CEO and General Counsel, while institutional ownership stands high at 98.39%.
Rocket Pharmaceuticals advances year round advocacy with EveryLife Foundation partnership
Rocket Pharmaceuticals is expanding its support for the rare disease community through a year-round partnership with the EveryLife Foundation for Rare Diseases, emphasizing that its advocacy extends beyond a single event like Rare Disease Day. The company aims to drive continuous progress for rare conditions by collaborating with patient advocacy groups, ensuring ongoing attention and resources for treatments and awareness. This commitment is further demonstrated by showcasing gene therapy advancements for immune disorders and presenting new science on LAD I at upcoming workshops.
Gene therapy for inborn immune errors takes center stage in Rocket Pharmaceuticals expert forum
Rocket Pharmaceuticals is hosting an expert forum tomorrow, March 25th, at 12 pm ET to discuss the latest advancements in gene therapy for inborn errors of immunity. The event will feature leading immunologists, Dr. Donald B. Kohn and Dr. Jordan Orange, and is part of Info4PI’s Speaker Series, focusing on breakthroughs for patients with genetic immune system disorders. This initiative aligns with Rocket Pharmaceuticals' ongoing commitment to advancing treatments for primary immune deficiencies, building on previous presentations at the Primary Immune Deficiency Treatment Consortium workshop.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Rating of "Hold" by Brokerages
Brokerages have given Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) an average rating of "Hold" based on analyst coverage, with a 12-month average price target of approximately $13.79. Recent insider transactions show executives selling shares, reducing overall insider ownership to 24.76%. The company's shares opened higher, reporting better-than-expected quarterly EPS of -$0.38 against an estimate of -$0.42.
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) added to S&P Biotechnology Select Industry Index
Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) has been added to the S&P Biotechnology Select Industry Index. The article also provides a company profile outlining Rocket Pharmaceuticals as a late-stage biotechnology firm focused on genetic therapies for rare disorders, with programs targeting conditions like Fanconi Anemia and Leukocyte Adhesion Deficiency-I. Additionally, it lists recent news and financial data points for the company.
RCKT Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for RCKT, including historical data, future forecasts, and how earnings reports typically affect the stock price. It highlights analyst estimates for upcoming quarters, past earnings surprises, and the correlation between forecast revisions and stock movements. The article also includes a section answering frequently asked questions about RCKT's earnings performance and outlook.
Rocket Pharma Advances BAG3 Heart Disease Study, Bolstering Long-Term Gene Therapy Story
Rocket Pharmaceuticals (RCKT) has initiated an observational study to track the progression of BAG3-related dilated cardiomyopathy (DCM) in adults. This study aims to gather critical data for designing future gene therapy trials and is not testing a new drug. The advancement of this natural history study supports Rocket’s long-term strategy in genetic cardiomyopathies, though it is not expected to generate near-term revenue.
Morgan Stanley names Rocket Pharmaceuticals (RCKT) as key beneficiary of 2026 biotech sector recovery
Morgan Stanley has identified Rocket Pharmaceuticals (RCKT) as a prime candidate to benefit from a projected recovery in the biotech sector starting in 2026. The investment bank anticipates that RCKT's strategic positioning will allow it to capitalize on improved market conditions and investor sentiment within biotechnology.
Rocket Pharmaceuticals to present LAD I advances at primary immune deficiency workshop
Rocket Pharmaceuticals is scheduled to present advancements in LAD I research at the 2026 Primary Immune Deficiency Treatment Consortium Annual Workshop on March 19 at 4:20 pm MT. This participation underscores the company's continuous dedication to developing treatments for rare immune disorders. Interested individuals can find more information about Rocket Pharmaceuticals' scientific developments through their official channels.
Rocket Pharmaceuticals Launches New $100M At-The-Market Program
Rocket Pharmaceuticals (RCKT) announced a new at-the-market equity offering program with Cantor Fitzgerald & Co., allowing it to sell up to $100 million of common stock. This replaces a previous agreement with Cowen and Company, LLC. The company's financial performance, including a lack of revenue and persistent losses, has resulted in a "Neutral" rating from TipRanks' AI Analyst, Spark, despite supportive technical indicators.
Suvretta Capital Management LLC Cuts Position in Rocket Pharmaceuticals, Inc. $RCKT
Suvretta Capital Management LLC reduced its stake in Rocket Pharmaceuticals (NASDAQ: RCKT) by 7.2% in the third quarter, selling 300,000 shares, but still holds 3.55% of the company. Despite this, other institutions like AQR Capital Management and Millennium Management increased their holdings significantly. Rocket Pharmaceuticals, a clinical-stage biopharmaceutical company, has a consensus "Hold" rating from analysts with an average price target of $13.79.
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 4.8% - Should You Sell?
Rocket Pharmaceuticals (NASDAQ: RCKT) saw its shares drop 4.8% on Wednesday, with trading volume significantly lower than average. Despite a consensus "Hold" rating from Wall Street analysts and a positive earnings surprise, insiders have reduced their ownership by selling shares. Institutional investors, however, have been increasing their positions in the company.
[EFFECT] ROCKET PHARMACEUTICALS, INC. SEC Filing
Rocket Pharmaceuticals, Inc. (RCKT) had an EFFECT filing on March 11, 2026, which is an SEC filing indicating the effectiveness of a registration statement. The filing details include the effectiveness date of March 10, 2026, for a Form S-3. The article also provides recent news and SEC filings for Rocket Pharmaceuticals.
Rocket Pharmaceuticals (RCKT) launches $100M at-the-market stock offering with Cantor
Rocket Pharmaceuticals (RCKT) has initiated a new "at-the-market" stock offering program, allowing it to sell up to $100 million of common stock through Cantor Fitzgerald & Co. as its sales agent. This new agreement replaces a previous arrangement with Cowen and Company, LLC. The shares will be issued under an existing S-3 shelf registration statement, with Cantor Fitzgerald receiving a commission of up to 3.0% of the gross proceeds.
Rocket Pharmaceuticals Launches New $100M At-The-Market Program
Rocket Pharmaceuticals (RCKT) has initiated a new $100 million at-the-market equity offering program with Cantor Fitzgerald & Co., allowing it to sell common stock to fund operations. This move replaces a previous agreement with Cowen and Company, LLC, indicating a strategic change in its capital-raising approach. Despite this financial maneuver, TipRanks' AI Analyst, Spark, rated RCKT as "Neutral" due to weak financial performance marked by no revenue, persistent losses, and ongoing cash burn.
Rocket Pharmaceuticals (RCKT) Launches $100 Million Stock Offeri
Rocket Pharmaceuticals (RCKT) has announced an at-the-market offering to raise up to $100 million, aiming to strengthen its financial position and fund its gene therapy development for rare pediatric diseases. Despite a strong balance sheet and institutional interest, the company faces significant challenges including a lack of revenue, profitability issues, and operational inefficiencies, suggesting it is a "Distressed" stock with high volatility. Investors are advised to carefully consider these risks alongside its potential.
Rocket Pharmaceuticals Launches $100 Million ATM Offering With Cantor Fitzgerald
Rocket Pharmaceuticals (RCKT) has initiated a new "at-the-market" equity sales agreement with Cantor Fitzgerald, allowing it to sell up to $100 million in common stock. This new agreement replaces a previous one with Cowen and Company, which was terminated on March 10, 2026. The move aims to provide the company with flexible access to equity capital.
According to the latest filing with the U.S. Securities and Exchange Commission, biotechnology company Rocket Pharmaceuticals, Inc. has officially signed an equity sales agreement with renowned financial institution Cantor Fitzgerald & Co.
Rocket Pharmaceuticals, Inc. has entered into an equity sales agreement with Cantor Fitzgerald & Co. for an At-the-Market (ATM) offering program, aiming to raise up to $100 million. This financing mechanism allows the biotechnology company to strategically issue common stock and secure funds to advance its gene therapy development pipeline for rare diseases. The details of this agreement have been filed with the U.S. SEC.
Form 424B5 ROCKET PHARMACEUTICALS,
Rocket Pharmaceuticals has filed a Form 424B5 prospectus supplement to offer up to $100,000,000 of common stock through Cantor Fitzgerald & Co. as its sales agent in an "at the market offering." The company plans to use the net proceeds primarily for general corporate purposes and working capital. This offering follows the termination of a prior sales agreement and a strategic corporate reorganization announced in July 2025 focusing on its AAV cardiovascular gene therapy platform.
According to the latest filing with the U.S. Securities and Exchange Commission, biotechnology company Rocket Pharmaceuticals, Inc. has officially signed an equity sales agreement with renowned financial institution Cantor Fitzgerald & Co.
Rocket Pharmaceuticals, Inc., a biotechnology company, has entered into an At-the-Market (ATM) equity sales agreement with Cantor Fitzgerald & Co. The agreement allows Rocket Pharmaceuticals to raise up to $100 million by issuing common stock flexibly based on market conditions. This financing will support the company's development of gene therapies for rare diseases.
According to the latest filing with the U.S. Securities and Exchange Commission, biotechnology company Rocket Pharmaceuticals, Inc. has officially signed an equity sales agreement with renowned financial institution Cantor Fitzgerald & Co.
Rocket Pharmaceuticals, Inc., a biotechnology company, has entered into an equity sales agreement with Cantor Fitzgerald & Co. The agreement establishes an At-the-Market (ATM) offering program allowing Rocket Pharmaceuticals to raise up to $100 million by issuing common stock as needed. This financing strategy aims to provide significant funding for their gene therapy development while optimizing the timing for capital raising.
Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances
Wedbush Securities maintains its 'outperform' rating and $16 price target for Rocket Pharmaceuticals, believing the company is significantly undervalued. The bullish stance comes as Rocket Pharmaceuticals plans to resume patient dosing in its pivotal Phase 2 study for Danon disease in the first half of 2026, with potential FDA data review completion by year-end. Additionally, the company is expanding its cardiac pipeline with a new program targeting BAG3-dilated cardiomyopathy, set to enter Phase 1 clinical testing in mid-2026.
Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances
Wedbush Securities has reiterated its "outperform" rating for Rocket Pharmaceuticals, citing the company's progress in its cardiac gene therapy pipeline. The broker believes the stock is significantly undervalued, maintaining a $16 price target against the current trading price of $4.97. Key advancements include the resumption of patient dosing for its Phase 2 Danon disease study and the upcoming Phase 1 trial for RP-A701 targeting BAG3-dilated cardiomyopathy.
Rocket Pharmaceuticals (NASDAQ: RCKT) files $400M shelf to raise capital
Rocket Pharmaceuticals, Inc. (RCKT) has filed an S-3 shelf registration statement to periodically offer up to $400 million in various securities, including common stock, preferred stock, debt securities, warrants, and units. This filing provides the company with flexibility to raise capital as needed, with specific terms for each offering to be detailed in future prospectus supplements. As of March 2, 2026, Rocket Pharmaceuticals had 108,569,143 shares of common stock outstanding.
Rocket Pharmaceuticals Q4 2025 Financial Report & Annual Results - News and Statistics
Rocket Pharmaceuticals Inc. announced its financial results for the fourth quarter of 2025, reporting a net loss of 38 cents per share, which was better than analysts' forecasts. For the full year, the biotechnology firm-reported a larger net loss of $2.01 per share. This report also discusses the broader antisera industry in the United States, providing an outlook to 2035 with detailed market analysis and forecasts.
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
Rocket Pharmaceuticals (RCKT) reported a Q4 2025 loss of 38 cents per share, which was narrower than the estimated 42 cents. The company, which currently has no marketed product, saw its shares rise 6.4% in after-hours trading and has made significant pipeline progress, including the FDA's acceptance of the BLA for Kresladi and the upliftment of the clinical hold on its pivotal phase II study for RP-A501. Rocket Pharmaceuticals expects its current cash balance to fund operations into Q2 2027.
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 14.3% Following Earnings Beat
Rocket Pharmaceuticals (NASDAQ:RCKT) saw its stock price jump 14.3% following a better-than-expected earnings report, with the company reporting ($0.38) EPS against an estimated ($0.42). Despite a consensus "Hold" rating from analysts, insider selling has occurred, coupled with significant institutional investor activity. The biotechnology company focuses on developing gene therapies for rare pediatric diseases.
Cantor Fitzgerald Raises Rocket Pharmaceuticals (RCKT) Price Tar
Cantor Fitzgerald has increased its price target for Rocket Pharmaceuticals (RCKT) to $10.00 from $8.00, maintaining an "Overweight" rating. This adjustment reflects continued confidence in the biotechnology company, which focuses on developing gene therapies for rare pediatric diseases. Despite variable historical analyst ratings, the current average analyst price target for RCKT suggests a potential upside of 56.05% from its current price.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of "Hold" from Analysts
Rocket Pharmaceuticals (NASDAQ: RCKT) has received an average "Hold" rating from 17 analysts, with a mean 12-month price target of $14.36. The company recently reported a better-than-expected quarterly loss of $(0.38) per share, surpassing the consensus of $(0.42). Insider transactions show sales by the CEO and General Counsel in February, though institutional ownership remains high at about 98.4%.
[8-K] ROCKET PHARMACEUTICALS, INC. Reports Material Event | RCKT SEC Filing - Form 8-K
Rocket Pharmaceuticals (RCKT) reported a Q4 2025 net loss of $42,538 and a full-year 2025 net loss of $223,123, significantly improving from the previous year. The company's total operating expenses decreased, and its cash position of $188.9 million is expected to fund operations into Q2 2027. Rocket highlighted progress in its cardiovascular gene therapy programs, including the expected resumption of the RP-A501 trial, a PDUFA date for KRESLADI™, and anticipated first dosing for RP-A701.
Rocket Pharmaceuticals: Fourth Quarter Financial Results Overview
Rocket Pharmaceuticals Inc. reported a net loss of $42.5 million, or 38 cents per share, for the fourth quarter, which was better than analysts' average forecast of a 42-cent loss per share. For the full year, the company had a total net loss of $223.1 million, or $2.01 per share. Financial data was provided by Zacks Investment Research.
Rocket Pharmaceuticals: Q4 Earnings Snapshot
Rocket Pharmaceuticals Inc. (RCKT) reported a fourth-quarter loss of $42.5 million, or 38 cents per share, surpassing Wall Street's expectation of a 42-cent loss. For the entire year, the company's loss totaled $223.1 million, or $2.01 per share. The financial results highlight the company's performance relative to analyst estimates.
Rocket Pharmaceuticals (NASDAQ:RCKT) Posts Earnings Results, Beats Expectations By $0.04 EPS
Rocket Pharmaceuticals (NASDAQ:RCKT) announced its quarterly earnings, reporting an EPS of ($0.38), which beat the consensus estimate by $0.04. The stock saw a trading increase to $4.53, with a market capitalization of $490 million, despite some insider selling by the CEO and General Counsel. Analysts currently hold a consensus "Hold" rating for RCKT with an average price target of $14.36.
